Engineering plant suspension cell cultures to produce pharmaceutical-grade cannabinoids with unmatched yield, purity, and scalability — without soil, sun, or seasonal constraint.
Targeted overexpression of rate-limiting enzymes in the MEP and polyketide pathways boosts cannabinoid flux by orders of magnitude within optimised suspension cultures.
DXS · CBGAS · OACJasmonates and UV elicitation trigger secondary metabolite cascades on demand, allowing precise temporal control over which cannabinoids are expressed and at what titre.
MeJA · UV-B · salicylateStirred-tank and airlift bioreactor designs maintain optimal dissolved oxygen, pH, and nutrient gradients, enabling seamless scale from milligram to kilogram.
GMP · ISO-certified · 500LHigh-throughput clonal screening identifies cell lines with superior genetic stability, growth kinetics, and cannabinoid-accumulating phenotypes before scale-up begins.
Cannabis sativa · callus · hairy rootInline LC-MS and Raman spectroscopy feed continuous process data into our ML models, enabling adaptive bioprocess control and yield prediction with <5% error.
PAT · in-line · predictiveTwo-stage chromatographic purification and preparative HPLC deliver pharmaceutical-grade isolates meeting USP and EU pharmacopoeia specifications for research and clinical use.
>99% purity · CoA guaranteedPyruvate and glyceraldehyde-3-phosphate condense via DXS to form the universal C₅ isoprene building blocks IPP and DMAPP, the entry point for all terpenoids.
Geranyl diphosphate synthase (GPPS) catalyses the head-to-tail condensation of IPP and DMAPP to form GPP, the direct monoterpene precursor fed into cannabinoid assembly.
Hexanoyl-CoA is extended by olivetol synthase (OLS) and cyclised by olivetolic acid cyclase (OAC) to produce olivetolic acid, the phenolic moiety of all cannabinoids.
Cannabigerolic acid synthase (CBGAS) geranylates olivetolic acid with GPP to yield CBGA — the universal precursor from which all acidic cannabinoid forms derive.
FAD-dependent oxidases THCAS, CBDAS, and CBCAS act competitively on CBGA. Enzyme expression ratios in our engineered lines determine the final cannabinoid profile.
Nadia Galazi brings over two decades of professional experience in regulated environments, including FCA-regulated firms and AIM-listed group structures. She has served as Company Secretary across various public limited companies and held Finance Director roles with responsibility for financial management, governance frameworks, and statutory compliance.
Her experience spans complex corporate transactions including share-for-share exchanges, group restructurings, and governance implementation across multi-jurisdictional entities. She previously served as a director of Newgate Solutions Ltd, a subsidiary of NextGate Solutions, Inc. (Pasadena, California) — a healthcare technology company acquired by Rhapsody, backed by Hg Capital, in March 2022.
She served as Compliance Officer and Deputy AML Manager at AGK Partners, Chartered Accountants, London, for over 20 years, overseeing anti-money laundering frameworks, regulatory compliance, and governance oversight.
Karl E. Watkin MBE is the owner and controlling shareholder of Menelaus Holding FZ LLC and Phytocyte Pty Ltd. An entrepreneur, strategist, and inspirational leader with a proven track record of identifying and developing emerging technologies, Mr. Watkin has raised over $1 billion in investment funds across his career.
A climate change activist for 25 years, he chaired the United Nations Foundation Bio Energy Board for five years and served as a United Nations Delegate at New York, Copenhagen, and Bali. He has chaired and delivered white papers on Climate Change Mitigation and Adaptation for the UNF, implemented worldwide.
Mr. Watkin is currently leading the development of pharmaceutical and bioscience technologies across the UK, Australia, New York, Hong Kong, and Vietnam. He has specialised in developing start-up businesses for 40 years, successfully bringing those businesses from concept to IPO.
Official filings submitted by Bakhu Holdings Corporation Inc to the U.S. Securities and Exchange Commission. Links to annual reports, quarterly disclosures, current event notices, and other mandatory regulatory documents are maintained below.
Comprehensive yearly overview of the company's financial performance, risk factors, and business operations.
Unaudited financial statements and management discussion filed within 45 days of each fiscal quarter end.
Material events disclosed to shareholders on an as-needed basis — acquisitions, leadership changes, and significant agreements.
Securities registration documents filed ahead of public offerings or exchange listings.
Definitive proxy statements providing shareholders with information required to vote at annual and special meetings.
Paste the SEC EDGAR or direct document URL, select the filing type, then click Add.
Add links to publications, datasets, media coverage, or any resource associated with Bakhu Holdings.
Partner with Bakhu Holdings Corporation Inc to co-develop custom cannabinoid production programmes tailored to your research or commercial pipeline.